Evaluation of Cardiovascular Risks Among the Participants of the EAPC Congress 2026 (EAPC-CVRISK 20)

August 18, 2026 updated by: European Society of Cardiology

Cross-Sectional Assessment of Cardiovascular Risk Among EAPC Congress 2026 Participants

The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens.

In line with this call for public health diagnosis of CV health, the ESC, through the European Association of Preventive Cardiology (EAPC), is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Preventive Cardiology Congress 2026 from 23-24 April 2026 in Ljubljana, Slovenia.

The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.

Study Overview

Status

Completed

Conditions

Cardiovascular Risks

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

511

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Slovenia
- - Ljubljana, Slovenia, 1000
    - Cankarjev Dom

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

All adults attendees (including healthcare professional) attending the EAPC Congress 2026 from 23 and 24 April in Ljubljana

Description

Inclusion Criteria:

All attendees including healthcare professionals (doctors, nurses, etc.) attending the EAPC Congress 2026 from 23 to 24 April 2026
Subjects who declare that they are able to understand and give informed consent in English

Exclusion Criteria:

Subjects not willing to provide his/her consent to participate in the study.
Subjects who are not suitable candidates for blood extraction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline Time Frame: Baseline	Baseline
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baseline Time Frame: Baseline	Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Society of Cardiology

Investigators

Study Chair: Zlatko Fras, Division of Medicine, Centre for Preventive Cardiology, University Medical Centre, Slovenia
Study Chair: Tim Kambič, Department of Medical Sciences in Sport and Exercise, Faculty of Sport, University of Ljubljana, Slovenia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 23, 2026

Primary Completion (Actual)

April 24, 2026

Study Completion (Actual)

April 24, 2026

Study Registration Dates

First Submitted

May 18, 2026

First Submitted That Met QC Criteria